How to buy Gilead Sciences (GILD) stocks

Gilead Sciences is a drug manufacturers - general business based in the US. Gilead Sciences shares (GILD) are listed on the NASDAQ and all prices are listed in US Dollars.

Its last market close was $111.44 – a decrease of 4.92% over the previous week. Gilead Sciences employs 17,600 staff and has a trailing 12-month revenue of around $28.8 billion.

Our top picks for where to buy Gilead Sciences stock

Buy Gilead Sciences stock from these online trading platforms

Compare special offers, low fees and a wide range of investment options among top trading platforms.

Note: The dollar amounts in the table below are in Canadian dollars.

Finder Score for stock trading platforms

To make comparing even easier we came up with the Finder Score. Trading costs, account fees and features across 10+ stock trading platforms and apps are all weighted and scaled to produce a score out of 10. The higher the score the better the platform - simple.

Read the full methodology

Related: Compare the best stock trading platforms in Canada

Gilead Sciences stock price (NASDAQ: GILD)

Use our graph to track the performance of GILD stocks over time.

Gilead Sciences stocks at a glance

• Key figures

Information last updated 2025-03-13.

Latest market close	$111.44
52-week range	$59.82 - $119.12
50-day moving average more info button	$101.24
200-day moving average more info button	$85.51
Wall St. target price	$111.26
PE ratio more info button	298.2895
Dividend yield more info button	$3.08 (2.77%)
Earnings per share (TTM) more info button	$0.38

Is it a good time to buy Gilead Sciences stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Dive deeper: Our picks for the best stocks to buy right now in Canada

Gilead Sciences price performance over time

Historical closes compared with the close of $111.44 from 2025-03-14

1 week (2025-03-10)	-4.92%
1 month (2025-02-14)	7.07%
3 months (2024-12-17)	20.09%
6 months (2024-09-17)	34.18%

1 year (2024-03-15)	51.23%
2 years (2023-03-17)	55.45%
3 years (2022-03-17)	111.59%
5 years (2020-03-17)	83.01%

Is Gilead Sciences stock undervalued or overvalued?

Valuing Gilead Sciences stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Gilead Sciences's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.

Gilead Sciences's P/E ratio

Gilead Sciences's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 298x. In other words, Gilead Sciences shares trade at around 298x recent earnings.

That's relatively high compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The high P/E ratio could mean that investors are optimistic about the outlook for the stock or simply that they're over-valued.

Gilead Sciences's PEG ratio

Gilead Sciences's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 0.2381. A low ratio can be interpreted as meaning the stocks offer better value, while a higher ratio can be interpreted as meaning the stocks offer worse value.

The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Gilead Sciences's future profitability. By accounting for growth, it could also help you if you're comparing the stock prices of multiple high-growth companies.

Gilead Sciences's EBITDA

Gilead Sciences's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $13.5 billion.

The EBITDA is a measure of a Gilead Sciences's overall financial performance and is widely used to measure a its profitability.

Gilead Sciences financials

Revenue TTM	$28.8 billion
Operating margin TTM	33.07%
Gross profit TTM	$22.5 billion
Return on assets TTM	11.03%
Return on equity TTM	2.29%
Profit margin	1.67%
Book value	$15.51
Market Capitalization more info button	$141.2 billion

TTM: trailing 12 months

Gilead Sciences's environmental, social and governance track record

Environmental, social and governance (known as ESG) criteria are a set of three factors used to measure the sustainability and social impact of companies like Gilead Sciences.

When it comes to ESG scores, lower is better, and lower scores are generally associated with lower risk for would-be investors.

Gilead Sciences's total ESG risk score

Total ESG risk: 22.15

Socially conscious investors use ESG scores to screen how an investment aligns with their worldview, and Gilead Sciences's overall score of 22.15 (as at 12/31/2018) is pretty good – landing it in it in the 31st percentile of companies rated in the same sector.

ESG scores are increasingly used to estimate the level of risk a company like Gilead Sciences is exposed to within the areas of "environmental" (carbon footprint, resource use etc.), "social" (health and safety, human rights etc.), and "governance" (anti-corruption, tax transparency etc.).

Gilead Sciences's environmental score

Environmental score: 0.53/100

Gilead Sciences's environmental score of 0.53 puts it squarely in the 2nd percentile of companies rated in the same sector. This could suggest that Gilead Sciences is a leader in its sector terms of its environmental impact, and exposed to a lower level of risk.

Gilead Sciences's social score

Social score: 12.97/100

Gilead Sciences's social score of 12.97 puts it squarely in the 2nd percentile of companies rated in the same sector. This could suggest that Gilead Sciences is a leader in its sector when it comes to taking good care of its workforce and the communities it impacts.

Gilead Sciences's governance score

Governance score: 7.65/100

Gilead Sciences's governance score puts it squarely in the 2nd percentile of companies rated in the same sector. That could suggest that Gilead Sciences is a leader in its sector when it comes to responsible management and strategy, and exposed to a lower level of risk.

Gilead Sciences's controversy score

Controversy score: 2/5

ESG scores also evaluate any incidences of controversy that a company has been involved in. Gilead Sciences scored a 2 out of 5 for controversy – the second-highest score possible, reflecting that Gilead Sciences has, for the most part, managed to keep its nose clean.

Environmental, social, and governance (ESG) summary

Gilead Sciences Inc was last rated for ESG on: 2019-01-01.

Total ESG score	22.15
Total ESG percentile	30.98
Environmental score	0.53
Environmental score percentile	2
Social score	12.97
Social score percentile	2
Governance score	7.65
Governance score percentile	2
Level of controversy	2

Gilead Sciences stock dividends

Dividend payout ratio: 67.25% of net profits

Recently Gilead Sciences has paid out, on average, around 100% of net profits as dividends. That has enabled analysts to estimate a "forward annual dividend yield" of 0% of the current stock value. This means that over a year, based on recent payouts (which are sadly no guarantee of future payouts), Gilead Sciences shareholders could enjoy a 0% return on their shares, in the form of dividend payments. In Gilead Sciences's case, that would currently equate to about $3.08 per share.

Gilead Sciences's payout ratio would broadly be considered high, and as such this stock could appeal to those looking to generate an income. Bear in mind however that companies should normally also look to re-invest a decent amount of net profits to ensure future growth.

Gilead Sciences's most recent dividend payout was on 27 March 2025. The latest dividend was paid out to all shareholders who bought their stocks by 13 March 2025 (the "ex-dividend date").

Have Gilead Sciences's stocks ever split?

Gilead Sciences's stocks were split on a 2:1 basis on 27 January 2013 . So if you had owned 1 share the day before before the split, the next day you'd have owned 2 shares. This wouldn't directly have changed the overall worth of your Gilead Sciences stocks – just the quantity. However, indirectly, the new 50% lower stock price could have impacted the market appetite for Gilead Sciences stocks, which in turn could have impacted Gilead Sciences's stock price.

Gilead Sciences stock price volatility

Over the last 12 months, Gilead Sciences's stocks have ranged in value from as little as $59.8241 up to $119.1239. A popular way to gauge a stock's volatility is its "beta."

Beta is a measure of a stocks volatility in relation to the market. The market (NASDAQ average) beta is 1, while Gilead Sciences's is 0.236. This would suggest that Gilead Sciences's stocks are less volatile than average (for this exchange).

Gilead Sciences overview

Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines for virology, oncology and other therapeutic areas in the United States, Europe, and internationally. The company offers Biktarvy, Genvoya, Descovy, Odefsey, Complera/Eviplera, Symtuza, Truvada, Stribild, and Sunlenca products for the treatment of HIV-1 infection; Veklury, an injection for intravenous use for the treatment of COVID-19; and Epclusa, Vemlidy, Harvoni, Viread, and Livdelzi for the treatment of liver disease. It also provides Yescarta, Tecartus, and Trodelvy products for the treatment of oncology; Letairis, an oral formulation for the treatment of pulmonary arterial hypertension; and AmBisome, a liposomal formulation for the treatment of serious invasive fungal infections. In addition, the company's portfolio of market products includes Atripla, Cayston, Descovy for PrEP, Emtriva, Hepcludex, Hepsera, Jyseleca, Sovaldi, Truvada for PrEP, Tybost, Vosevi, and Zydelig. It has collaboration agreements with Arcellx, Inc.; Merck & Co.

Related: New to stock trading? Compare brokers and get tips for investing.

Frequently asked questions

What percentage of Gilead Sciences is owned by insiders or institutions?
Currently 0.109% of Gilead Sciences stocks are held by insiders and 89.728% by institutions. How many people work for Gilead Sciences?
Latest data suggests 17,600 work at Gilead Sciences. When does the fiscal year end for Gilead Sciences?
Gilead Sciences's fiscal year ends in December. Where is Gilead Sciences based?
Gilead Sciences's address is: 333 Lakeside Drive, Foster City, CA, United States, 94404 What is Gilead Sciences's ISIN number?
Gilead Sciences's international securities identification number is: US3755581036 What is Gilead Sciences's CUSIP number?
Gilead Sciences's Committee on Uniform Securities Identification Procedures number is: 375558103

Disclaimer: This information should not be interpreted as an endorsement of futures, stocks, ETFs, options or any specific provider, service or offering. It should not be relied upon as investment advice or construed as providing recommendations of any kind. Futures, stocks, ETFs and options trading involves substantial risk of loss and therefore are not appropriate for all investors. Trading forex on leverage comes with a higher risk of losing money rapidly. Past performance is not an indication of future results. Consider your own circumstances, and obtain your own advice, before making any trades.